185 related articles for article (PubMed ID: 32419364)
21. [Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: a meta analysis].
Yuan Q; Chen X; Cheng L; Zhou CH; Fu XM; Li YP; Wang NH; Wang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):412-20. PubMed ID: 21906451
[TBL] [Abstract][Full Text] [Related]
22. The clinical characteristics of patients with acute leukemia or stem cell transplantation exhibiting immune based platelet refractoriness.
Zhou Z; Gao Y; Li X; Ren J; Liu Y; Li J
Transfus Apher Sci; 2020 Jun; 59(3):102725. PubMed ID: 31974031
[TBL] [Abstract][Full Text] [Related]
23. Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation for Adults: Risk Factors and Clinical Outcomes.
Tanoue S; Konuma T; Kato S; Oiwa-Monna M; Isobe M; Jimbo K; Takahashi S; Tojo A
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1873-1880. PubMed ID: 29753839
[TBL] [Abstract][Full Text] [Related]
24. Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes.
Fu Q; Xu L; Zhang X; Wang Y; Chang Y; Liu K; Huang X
Sci China Life Sci; 2018 May; 61(5):569-577. PubMed ID: 28914433
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
27. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
Pappalardo PA; Secord AR; Quitevis P; Haimowitz MD; Goldfinger D
Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of transfusion effect of different platelet matching schemes in patients with platelet transfusion refractoriness].
Liang YJ; Wang H; Zhao PZ; Wang F; Li Q; Xu Y; Wu YX; Zhang DM; He XH
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(11):865-869. PubMed ID: 38462363
[No Abstract] [Full Text] [Related]
29. The loss or absence of minimal residual disease of <0ยท1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Duan W; Liu X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Zhao X; Qin Y; Shi H; Chang Y; Huang X; Jiang H
Br J Haematol; 2021 Jan; 192(2):265-271. PubMed ID: 32588434
[TBL] [Abstract][Full Text] [Related]
30. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness.
Beligaswatte A; Tsiopelas E; Humphreys I; Bennett G; Robinson K; Davis K; Bardy P
Br J Haematol; 2013 Aug; 162(3):409-12. PubMed ID: 23651440
[TBL] [Abstract][Full Text] [Related]
31. [Emergence of donor-derived anti-HLA antibody and subsequent transfusion-refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor in a patient with acute myeloid leukemia].
Uchiyama Y; Hoshino T; Mihara M; Mitsui T; Koiso H; Takizawa M; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Murakami H; Nojima Y
Rinsho Ketsueki; 2013 Feb; 54(2):214-8. PubMed ID: 23470830
[TBL] [Abstract][Full Text] [Related]
32. [Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients].
Xia WJ; Ye X; Deng J; Chen YK; Xu XZ; Ding HQ; Luo GP; Fu YS
Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):594-8. PubMed ID: 21122318
[TBL] [Abstract][Full Text] [Related]
33. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
34. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
Seike K; Fujii N; Asano N; Ohkuma S; Hirata Y; Fujii K; Sando Y; Nakamura M; Naito K; Saeki K; Meguri Y; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Tsubaki K; Otsuka F; Maeda Y
Transfusion; 2020 Mar; 60(3):473-478. PubMed ID: 31970799
[TBL] [Abstract][Full Text] [Related]
36. [The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia].
Wang F; Wang W; Liu M; Zhang Y; Chen X; Yuan LL; Ma XL; Nie DJ; Wang MY; Zhang Y; Zhang W; Liu MY; Liu HX
Zhonghua Yi Xue Za Zhi; 2020 Jan; 100(3):225-229. PubMed ID: 32008291
[No Abstract] [Full Text] [Related]
37. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
38. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia.
Nakazawa Y; Saito S; Hasegawa Y; Yanagisawa R; Sakashita K; Kamijo T; Miyazaki T; Sato S; Ikeda H; Ikebuchi K; Koike K
Transfusion; 2007 Feb; 47(2):326-34. PubMed ID: 17302780
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
40. Extent of transfusion support in a developing country in managing a bleeding acute myeloid leukemia patient with platelet transfusion refractoriness.
Chellaiya GK; Nair CK; Raghavan V; Pandian RJ; Vinod R; Murugesan M
Asian J Transfus Sci; 2021; 15(1):90-93. PubMed ID: 34349464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
